STAT4 (Ab-693) Antibody

What is the functional significance of STAT4 phosphorylation at Tyrosine 693?

Phosphorylation of STAT4 at tyrosine 693 (Y693) represents a critical activation marker in the STAT4 signaling pathway. When cytokines such as IL-12 or type I interferons bind to their respective receptors, they trigger the activation of Janus kinases (JAKs), which subsequently phosphorylate STAT4 at Y693. This phosphorylation event enables STAT4 dimerization, nuclear translocation, and DNA binding, ultimately leading to transcriptional regulation of target genes involved in T helper cell differentiation and immune function .

The phosphorylation state at Y693 serves as a direct indicator of STAT4 activation status and is essential for its biological function in promoting Th1 differentiation and inflammatory responses. Importantly, this phosphorylation site is highly conserved across species, appearing at Y693 in humans and mice, making it a reliable marker for activation across experimental models .

How do different cytokines influence STAT4 phosphorylation at Tyr693?

Different cytokines induce distinct patterns of STAT4 phosphorylation at Tyr693, which contributes to their specific immunological outcomes:

Notably, IL-12 remains the most potent inducer of STAT4 phosphorylation. The differential response to type I IFNs between human and mouse T cells highlights important species-specific variations in STAT4 signaling that researchers must consider when designing experiments or translating findings between models .

How does STAT4 signaling contribute to immune cell differentiation?

STAT4 signaling plays a pivotal role in immune cell differentiation, particularly in the development of Th1 cells, which are critical for cell-mediated immunity against intracellular pathogens. Upon phosphorylation at Tyr693:

• STAT4 dimers translocate to the nucleus where they bind specific DNA elements and regulate gene expression

• This process promotes expression of T-bet, the master transcription factor for Th1 differentiation

• STAT4 signaling enhances production of IFNγ, a signature cytokine of Th1 responses

• It is required for optimal Th1 differentiation in vivo, as demonstrated in experimental models

Recent research has also revealed roles for STAT4 in regulating other T cell subsets, including Th17 cells, which contribute to various autoimmune conditions. Additionally, STAT4 is necessary for normal development, maturation, and activation of natural killer (NK) cells, providing a broader impact on innate and adaptive immunity beyond Th1 responses alone .

What are the optimal protocols for detecting phospho-STAT4 (Tyr693) in different experimental systems?

The detection of phospho-STAT4 (Tyr693) requires specific protocols optimized for the preservation of phosphorylation status. Below are recommended approaches for different experimental techniques:

For Flow Cytometry:
The two-step fixation/methanol protocol is strongly recommended for phospho-STAT4 detection:

• Use Protocol C: Two-step protocol with Fixation/Methanol

• Do NOT use Protocol A (for cytoplasmic proteins) or Protocol B (for nuclear proteins)

• Typical antibody usage: 5 μL (0.25 μg) per test in 100 μL staining volume

• Cell numbers can range from 10^5 to 10^8 cells/test, but should be optimized empirically

For Western Blotting:

• Recommended dilutions range from 1:500-1:1,000

• Expected band size: approximately 81-85 kDa

• Protein extraction should occur rapidly after stimulation to capture phosphorylation events

For Immunohistochemistry:

• Typical dilutions range from 1:50-1:100

• Antigen retrieval methods should be optimized based on tissue fixation

For Chromatin Immunoprecipitation:

• Use 20 μl of antibody and 10 μg of chromatin (approximately 4 x 10^6 cells) per IP

• Follow validated ChIP protocols specifically designed for phosphorylated transcription factors

How can researchers validate the specificity of phospho-STAT4 (Tyr693) antibodies?

Validating antibody specificity is crucial for ensuring reliable results. For phospho-STAT4 (Tyr693) antibodies, researchers should employ multiple validation strategies:

• Positive and negative controls:

  • Use cells stimulated with IL-12 (strong inducer) as positive controls

  • Include unstimulated cells as negative controls

  • Consider STAT4-knockout or STAT4-depleted cells as specificity controls

• Phosphatase treatment:

  • Treat duplicate samples with lambda phosphatase to remove phosphorylation

  • Confirm loss of signal after phosphatase treatment

• Peptide competition:

  • Pre-incubate antibody with phospho-peptide and non-phospho-peptide

  • Signal should be blocked by phospho-peptide but not by non-phospho-peptide

  • Some commercial antibodies are already validated this way: "Affinity-purified on phosphopeptide; non-phosphopeptide reactive antibodies were removed by chromatography on non-phosphorylated peptide"

• Cross-validation with different antibody clones:

  • Compare results from monoclonal (e.g., 4LURPIE) and polyclonal antibodies

  • Consistent results across different antibodies increase confidence in specificity

What stimulation conditions are recommended for studying phospho-STAT4 (Tyr693) in different cell types?

Optimal stimulation conditions vary by cell type and research question:

For optimal detection, stimulation should be performed in serum-free or low-serum media to reduce background phosphorylation. Samples should be processed rapidly after stimulation, as phosphorylation events can be transient, particularly with IFNα stimulation in mouse cells .

Why might phospho-STAT4 (Tyr693) signal be weak or inconsistent despite proper stimulation?

Several factors can contribute to weak or inconsistent phospho-STAT4 (Tyr693) signals:

• Rapid dephosphorylation:

  • Phosphorylation is dynamic and can be rapidly reversed by phosphatases

  • Solution: Use phosphatase inhibitors during sample preparation and process samples quickly

• Species-specific differences:

  • IFNα stimulation produces stronger phospho-STAT4 signals in human cells than in mouse cells

  • IFNα-induced phosphorylation is "much weaker than that induced by IL-12 and is transient" in mouse T cells

  • Solution: Use IL-12 stimulation for more consistent results across species

• Cell type heterogeneity:

  • STAT4 expression and activation varies between cell types

  • STAT4 is activated by IL-2 in NK cells but not in T cells

  • Solution: Consider cell sorting or gating strategies for flow cytometry

• Technical issues with fixation/permeabilization:

  • Phospho-epitopes can be sensitive to fixation conditions

  • Solution: Use recommended Protocol C (Two-step Fixation/Methanol) for flow cytometry

• Sample handling:

  • Freeze-thaw cycles can degrade phosphorylated proteins

  • Solution: Aliquot antibodies and avoid repeated freeze-thaw cycles; store at recommended temperatures (-20°C for long-term preservation)

How can researchers address non-specific binding when working with phospho-STAT4 (Tyr693) antibodies?

Non-specific binding is a common challenge with phospho-antibodies. To minimize this issue:

• Optimize blocking conditions:

  • Use appropriate blocking reagents (BSA, normal serum) matched to the host species of secondary antibodies

  • Consider longer blocking times (1-2 hours) for challenging samples

• Antibody titration:

  • Determine optimal antibody concentration through titration experiments

  • Follow recommended dilutions (e.g., 1:500-1:1,000 for WB; 1:50-1:100 for IHC)

• Use purified antibodies:

  • Many commercial phospho-STAT4 antibodies are affinity-purified specifically against phospho-peptides

  • Some preparations include removal of non-phospho-reactive antibodies: "Affinity-purified on phosphopeptide; non-phosphopeptide reactive antibodies were removed by chromatography on non-phosphorylated peptide"

• Include appropriate controls:

  • Isotype controls for monoclonal antibodies

  • Pre-immune serum for polyclonal antibodies

  • Consider using STAT4-deficient cells/tissues as negative controls

• Modify washing conditions:

  • Increase number and duration of washes

  • Add low concentrations of detergent (0.05-0.1% Tween-20) to reduce non-specific binding

How should differences in phospho-STAT4 (Tyr693) levels be interpreted across experimental conditions?

Interpreting phospho-STAT4 (Tyr693) data requires consideration of multiple factors:

• Baseline vs. stimulated conditions:

  • Minimal phosphorylation usually occurs in resting cells

  • Significant increases after stimulation indicate functional STAT4 signaling

  • The magnitude of increase relative to baseline is often more informative than absolute values

• Temporal dynamics:

  • Phosphorylation patterns differ by stimulus: IL-12 induces stronger, more sustained phosphorylation than IFNα

  • In mouse cells, "IFN alpha phosphorylation of STAT4 does not contribute to STAT4-mediated Th1 development"

  • Time-course experiments can reveal important biological differences in signaling kinetics

• Cell type-specific responses:

  • Compare phosphorylation patterns within similar cell types

  • Be cautious when comparing across different cell lineages, as baseline STAT4 expression varies

  • Remember that "STAT4 is activated in response to IL-2 in natural killer (NK) cells, but not in T-cells"

• Species differences:

  • Human and mouse cells show different responses to type I IFNs

  • "IFN alpha does promote Th1 development and function of human CD4+ T cells" but has limited effects in mice

  • Consider these differences when translating findings between model systems and human studies

What normalization approaches are recommended for quantifying phospho-STAT4 (Tyr693) by Western blotting?

Proper normalization is essential for accurate quantification of phospho-STAT4 levels:

• Normalization to total STAT4:

  • Ideally, measure phospho-STAT4 and total STAT4 on the same blot or parallel blots

  • Calculate phospho/total ratio to account for variations in STAT4 expression

  • This requires separate antibodies for phospho-STAT4 and total STAT4

• Loading control normalization:

  • Use housekeeping proteins (β-actin, GAPDH, tubulin) as loading controls

  • Consider nuclear loading controls (Lamin B, Histone H3) when analyzing nuclear fractions

  • Be aware that some commonly used loading controls may vary between experimental conditions

• Technical considerations:

  • When stripping and reprobing membranes, verify complete stripping to avoid residual signal

  • Consider running duplicate gels for probing with different antibodies if stripping is problematic

  • Include a standard curve of lysates to ensure measurements are within the linear range of detection

• Statistical analysis:

  • Perform experiments with biological replicates (n≥3)

  • Use appropriate statistical tests based on data distribution

  • Present both raw and normalized data when possible

How does STAT4 polymorphism rs7574865 affect phospho-STAT4 (Tyr693) levels and disease susceptibility?

The rs7574865 polymorphism in the STAT4 gene has significant implications for STAT4 function and disease risk:

• Molecular impact:

  • This SNP is associated with altered STAT4 mRNA expression levels

  • "rs7574865 at STAT4 with lower mRNA levels of STAT4 is significantly associated with the HBV-related HCC risk"

  • May influence the efficiency of STAT4 phosphorylation at Tyr693

• Disease associations:

  • Associated with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) risk

  • "rs7574865 at STAT4 is associated with the susceptibility of CHB induced HCC"

  • Also associated with chronic hepatitis B (CHB) susceptibility and HBV natural clearance

  • Linked to autoimmune conditions including systemic lupus erythematosus and rheumatoid arthritis

• Therapeutic relevance:

  • "STAT4 rs7574865 is a reliable predictor of response to IFNα therapy, a first-line therapy for CHB, in hepatitis B e antigen (HBeAg)-positive CHB patients"

  • Could serve as a biomarker for personalized treatment approaches

  • May influence the phosphorylation response to therapeutic cytokines

When studying this polymorphism, researchers should consider examining both total STAT4 expression and phospho-STAT4 (Tyr693) levels to understand the functional consequences of genetic variation.

What is the relationship between STAT4 activation and tumor suppression in liver cancer?

Research indicates STAT4 may function as a tumor suppressor in hepatocellular carcinoma:

• Expression patterns:

  • "STAT4 was reported to be expressed at lower levels in HCC than in normal liver tissues"

  • Lower expression correlates with clinical parameters: "associated with serum hepatitis B surface antigen (HBsAg) level, tumor number, tumor size, and severity of HCC"

• Functional mechanisms:

  • "STAT4 may modulate the pathological progression of HCC by inhibiting HCC cells proliferation, growth, and apoptosis, via acting as a tumor suppressor"

  • "STAT4 may regulate the IFNγ production by CD8+ T-cell infiltration of tumor tissue"

  • The phosphorylation state of STAT4 at Tyr693 likely mediates these effects through transcriptional regulation

• Clinical implications:

  • "Lower STAT4 expression showed higher incidence of recurrence after [hepatectomy]"

  • May serve as a prognostic marker for HCC

  • Could represent a potential therapeutic target

Researchers investigating STAT4's role in HCC should examine both total and phosphorylated STAT4 levels in tumor tissues compared to adjacent normal tissues, and correlate these with immune cell infiltration patterns, particularly CD8+ T cells.

How can phospho-STAT4 (Tyr693) be leveraged as a biomarker in autoimmune disease research?

Phospho-STAT4 (Tyr693) has potential as a biomarker in autoimmune disease research:

• Diagnostic applications:

  • May help identify dysregulated IL-12/STAT4 signaling in autoimmune conditions

  • Could distinguish between different autoimmune disease subtypes based on activation patterns

  • "STAT4 plays a pivotal role in the differentiation and proliferation of Th1 and Th17 cells, both of which are crucial effectors of chronic autoimmune disorders"

• Therapeutic monitoring:

  • Changes in phospho-STAT4 levels could indicate response to therapies targeting cytokine pathways

  • May help predict or monitor response to JAK inhibitors or other immunomodulatory drugs

  • Could serve as a pharmacodynamic marker in clinical trials

• Research applications:

  • Use as a readout for functional studies of STAT4 polymorphisms associated with disease risk

  • "Single nucleotide polymorphisms of STAT4 are implicated in the pathogenesis of systemic lupus erythematosis and rheumatoid arthritis"

  • Examine differential activation across immune cell subsets in patient samples

For methodological consistency in biomarker studies, researchers should standardize stimulation conditions, processing times, and detection methods to minimize technical variability that could confound biological differences between patient cohorts.